Systemic Sclerosis Antibodies

Comprehensive Systemic Sclerosis Panel 3000480
Method: Qualitative Immunoblot/Semi-Quantitative Indirect Fluorescent Antibody/Semi-Quantitative Multiplex Bead Assay/Semi-Quantitative Enzyme-Linked Immunosorbent Assay

Indicated when suspicion for SSc is high and patient presents with features of overlap syndrome

Individual tests in panel may be ordered separately. (See Related Tests.)

Criteria Systemic Sclerosis Panel 3000479
Method: Semi-Quantitative Indirect Fluorescent Antibody/Semi-Quantitative Multiplex Bead Assay/Semi-Quantitative Enzyme-Linked Immunosorbent Assay

Indicated for patients with distinct features of SSc

Negative results do not rule out SSc; if test is negative and suspicion for SSc is high, consider testing for U3 RNP (fibrillarin), PM/Scl-100, U1RNP, Th/Tho, or other connective tissue disease autoantibodies based on patient’s clinical presentation

Systemic sclerosis (SSc), also called scleroderma, is a chronic autoimmune disorder characterized by fibrosis of the skin and various organs.   Early diagnosis and classification are important so that patients can be evaluated for organ involvement and/or damage.  However, because SSc is a heterogeneous disease, clinical presentation and disease course vary, and manifestations may overlap with those of other rheumatic disorders, all of which can complicate diagnosis.    The initial testing strategy includes CBC with platelet count and automated differential and nuclear antibody (ANA) by IFA, IgG. Confirmatory or secondary testing should be performed based on ANA IFA patterns (centromere, nucleolar, and speckled patterns), clinical presentation, and/or ethnicity.

Disease Overview


0.3-2.8/100,000 worldwide 

Age of Onset

20-50 years of age 


M<F, 1:3 

Diagnostic Issues

Autoimmune connective tissue diseases may present with similar features, particularly early in disease, making diagnosis difficult. The following considerations may assist in determining a diagnosis of SSc:

  • ANA IFA patterns may help define diagnostic pathways
    • Most patients with SSc will have either :
      • Centromere antibodies
      • Scl-70 antibodies
      • RNA polymerase III antibodies
    • These three antibody tests are required for the initial evaluation of SSc although the use of other autoantibody markers may improve diagnostic sensitivity for disease
  • The presence of SSc-specific antibodies may help predict disease phenotypes, which include:
    • CREST (calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) syndrome: antibodies against centromere are most common 
    • Diffuse cutaneous SSc: antibodies against Scl-70 and RNA polymerase III most common
  • Antibody patterns may differ by ethnicity 
    • Antibodies against U3-RNP are more common in African Americans
    • Th/To autoantibodies are more common in Caucasians with limited cutaneous SSc

Test Interpretation

Clinical Sensitivity 

  • ANA by IFA for SSc: 90-95%
  • Individual SSc-specific marker: may vary based on ethnicity


  • ANA patterns (including centromere) are reported
  • If positive, pattern and titers are reported


  • Negative antibody test result does not exclude SSc (5-10% of patients with SSc are ANA IFA negative)  
  • Panel does not include Th/To
  1. Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, Rongioletti F, Denton CP, Rudnicka L, Frasin LA, Smith V, Gabrielli A, Aberer E, Bagot M, Bali G, Bouaziz J, Olesen B, Foeldvari I, Frances C, Jalili A, Just U, Kähäri V, Kárpáti S, Kofoed K, Krasowska D, Olszewska M, Orteu C, Panelius J, Parodi A, Petit A, Quaglino P, Ranki A, Schmidt JM, Seneschal J, Skrok A, Sticherling M, Sunderkötter C, Taieb A, Tanew A, Wolf P, Worm M, Wutte NJ, Krieg T. European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. J Eur Acad Dermatol Venereol. 2017; 31(9): 1401-1424. PubMed
  2. Salazar GA, Assassi S, Wigley F, Hummers L, Varga J, Hinchcliff M, Khanna D, Schiopu E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Taillefer SS, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Molitor JA, Fritzler MJ, Segal BM, Al-Kassab F, Perry M, Yang J, Zamanian S, Reveille JD, Arnett FC, Pedroza C, Mayes MD. Antinuclear antibody-negative systemic sclerosis. Semin Arthritis Rheum. 2015; 44(6): 680-6. PubMed
  3. Tartar DM, Chung L, Fiorentino DF. Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis. Clin Dermatol. 2018; 36(4): 508-524. PubMed
  4. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013; 72(11): 1747-55. PubMed
  5. Alba MA, Velasco C, Simeón CP, Fonollosa V, Trapiella L, Egurbide MV, Sáez L, Castillo MJ, Callejas JL, Camps MT, Tolosa C, Ríos JJ, Freire M, Vargas JA, Espinosa G, RESCLE Registry. Early- versus late-onset systemic sclerosis: differences in clinical presentation and outcome in 1037 patients. Medicine (Baltimore). 2014; 93(2): 73-81. PubMed
  6. Nandiwada SL, Peterson LK, Mayes MD, Jaskowski TD, Malmberg E, Assassi S, Satoh M, Tebo AE. Ethnic Differences in Autoantibody Diversity and Hierarchy: More Clues from a US Cohort of Patients with Systemic Sclerosis. J Rheumatol. 2016; 43(10): 1816-1824. PubMed

Last Update: October 2019